Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Abstract:
Nanobiotix, based in Paris, France, announces the closing of a $ 11 million series-C financing round. The company develops innovative therapeutic products for cancer using nanotechnologies.

Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Paris | Posted on May 3rd, 2010

Nanobiotix raised US 11 million from a strong new and existing syndicate of investors. CIC Vizille Capital Innovation has led this new round with Masseran Gestion. Existing shareholder have strongly participated in the round, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes.

"This successful closing is the recognition of the value of Nanobiotix breakthrough technology NanoXray. This financing will enable us to continue to advance our lead programs through clinical studies. We first plan on reinforcing our scientific /developpement team and resources: we are entering our first-in-man clinical study of nanoXray therapeutics with IGR Institut Gustave Roussy, - a Europe leading cancer treatment center - for Soft Tissue Sarcoma as initial indication. First preclinical data are very promising: safety in animals of NBTXR3 - when activated by ionizing radiation has been demonstrated; performance has clearly shown the potential of this product to become a new approach for cancer treatment," says Dr Laurent Levy, PhD, co-founder and CEO of Nanobiotix, a worldwide pioneer in nanomedicine.

"We are thrilled to be part of this very exciting adventure and pleased to help accelerate the development of a new class of cancer treatment, more effective and less deadly to healthy tissues. Nanobiotix has mastered the critical issues related to NanoXray reproductibility, scalability and stability," says Karine Lignel; CIC - Vizille Capital Innovation.

Since its creation in 2003, the company has made tremendous progresses and obtained significant results. It has a well balanced pipeline and a unique nanomedicine expertise in developing a very promising therapy for cancer treatment.

"We are confident in the development of Nanobiotix and its technology. We truly believe that is the best risk reward products in biotech field," says Jerome Snollaerts; Cap Decisif Management.

In parallel to the ongoing clinical developments, Nanobiotix has built an industrial and academic collaborative projects portfolio including research programs and industrial partnering, like Sonodrug with Philips Research or Biotech Corp in Malaysia.

"This is a significant step to the development of nanoXRay and we are excited to be that close to offer a potential alternative to patients," Patrick Langlois; Chairman of the non executive board.

####

About Nanobiotix
Nanobiotix is a leading nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop "nanoXray a technology platform that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

About NanoXray Platform
NanoXray therapeutic platform is designed to enable the precise destruction of cancer cells made possible by the controlled application of an outside the body energy source, in that case an X-ray. The nanoparticles that comprise the nanoXray platform allow for an extensive combination of therapeutic modalities and malignant pathologies. Nbtxr3, the first product to be developed from the nanoXray pipeline, also is the first-in-class product to be activated by radiotherapy. The intended initial indications for Nbtxr3 are:

Soft Tissue Sarcoma - Hepatic Cancer - Colon cancer - Lung cancer - Pancreatic cancer

Dr Laurent Levy will be attending BIO Chicago, from May 3 to May 6.

For more information, please click here

Contacts:
60 rue de Wattignies
Bat B 3rd floor
75012 Paris, France

Tel : + 33 (0) 1 40 26 04 70
Fax : +33 (0) 1 40 26 04 44

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Possible Futures

Printing Silicon on Paper, with Lasers April 21st, 2015

A glass fiber that brings light to a standstill: By coupling photons to atoms, light in a glass fiber can be slowed down to the speed of an express train; for a short while it can even be brought to a complete stop April 9th, 2015

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Nanotechnology Enabled Drug Delivery to Influence Future Diagnosis and Treatments of Diseases March 21st, 2015

Investments/IPO's/Splits

Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Graphenea embarks on a new era April 16th, 2015

Harris & Harris Group Portfolio Company OpGen Files Amended Registration Statement for Proposed Public Offering April 8th, 2015

Nanomedicine

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

Self-assembling biomaterial forms nanostructure templates for human tissue formation April 27th, 2015

International research team discovers new mechanism behind malaria progression: Findings provide a new avenue for research in malaria treatment April 27th, 2015

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

Announcements

New technique for exploring structural dynamics of nanoworld: Developed in a Nobel laureate's laboratory at Caltech, hybrid approach allows ultrafast EM analysis of materials, showing tiny electronic changes in individual atoms within a material on ultrafast time scales April 28th, 2015

When mediated by superconductivity, light pushes matter million times more April 28th, 2015

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

Sensor Designed in Iran Able to Remove Formaldehyde Gas from Environment April 27th, 2015

Nanobiotechnology

Self-assembling biomaterial forms nanostructure templates for human tissue formation April 27th, 2015

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Scientists Use Nanoscale Building Blocks and DNA 'Glue' to Shape 3D Superlattices: New approach to designing ordered composite materials for possible energy applications April 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project